<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Urteste S.a. — News on 6ix</title>
    <link>https://6ix.com/company/urteste-sa</link>
    <description>Latest news and press releases for Urteste S.a. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 06 Nov 2025 12:35:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/urteste-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683635a678dffbe2df14a3ac.webp</url>
      <title>Urteste S.a.</title>
      <link>https://6ix.com/company/urteste-sa</link>
    </image>
    <item>
      <title>Urteste S.A. launches European multicenter clinical study of the Panuri test</title>
      <link>https://6ix.com/company/urteste-sa/news/urteste-sa-launches-european-multicenter-clinical-study-of-the-panuri-test</link>
      <guid isPermaLink="true">https://6ix.com/company/urteste-sa/news/urteste-sa-launches-european-multicenter-clinical-study-of-the-panuri-test</guid>
      <pubDate>Thu, 06 Nov 2025 12:35:00 GMT</pubDate>
      <description>Urteste S.A. launches European multicenter clinical study of the Panuri test Gdańsk, Poland – 6 November 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for the early detection of cancer from urine samples, has entered into a tripartite agreement with Aurevia Poland and Aurevia Oy, based in Finland, for CRO services, including the organization and management of a European clinical study of the Panuri test — an IVD medical devic</description>
    </item>
    <item>
      <title>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025</title>
      <link>https://6ix.com/company/urteste-sa/news/urteste-sa-completes-development-of-panuri-test-company-plans-to-launch-clinical-study-in-q3-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/urteste-sa/news/urteste-sa-completes-development-of-panuri-test-company-plans-to-launch-clinical-study-in-q3-2025</guid>
      <pubDate>Mon, 21 Jul 2025 12:14:00 GMT</pubDate>
      <description>Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer detection using a unique method of urine sample analysis, has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer – one of the m</description>
    </item>
  </channel>
</rss>